Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04048850 · ClinicalTrials.gov registry record
Zepatier in Patients with Substance Use
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 25
- Enrollment target
NCT04048850: Completed study, sponsored by University of Illinois at Chicago.
NCT04048850 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04048850 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use in urban, multidisciplinary specialty clinics.
Primary Outcome
Proportion of patients in the per-protocol (PP) population with sustained virologic response (SVR). PP: excludes non-treatment related discontinuations and patients lost to follow-up before SVR-12 laboratory test.
Interventions
- DRUG Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2022-09-09 |
What the finished NCT04048850 record still lists
NCT04048850 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] is the first listed.
NCT04048850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04048850 about?
NCT04048850 is a clinical study titled "Zepatier in Patients with Substance Use". The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resis...
What is the current status of trial NCT04048850?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2019-09-20. Estimated completion is 2022-09-09.
What interventions are being tested in trial NCT04048850?
The interventions under investigation include: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] (DRUG).
Who is sponsoring clinical trial NCT04048850?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI